H
Hans Iko Huppertz
Researcher at Hess Corporation
Publications - 51
Citations - 2334
Hans Iko Huppertz is an academic researcher from Hess Corporation. The author has contributed to research in topics: Arthritis & Medicine. The author has an hindex of 15, co-authored 46 publications receiving 2156 citations.
Papers
More filters
Journal ArticleDOI
Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
Daniel J. Lovell,Nicolino Ruperto,Steven N. Goodman,Andreas Reiff,Lawrence Jung,Katerina Jarosova,Dana Nemcova,Richard Mouy,Christy Sandborg,John F. Bohnsack,Dirk Elewaut,Ivan Foeldvari,Valeria Gerloni,Jozef Rovensky,Kirsten Minden,Richard K. Vehe,L. Wagner Weiner,Gerd Horneff,Hans Iko Huppertz,Nancy Y. Olson,John R. Medich,Roberto Carcereri-De-Prati,Melissa J. McIlraith,Edward H. Giannini,Alberto Martini +24 more
TL;DR: Adalimumab therapy seems to be an efficacious option for the treatment of children with juvenile rheumatoid arthritis.
Journal ArticleDOI
The German etanercept registry for treatment of juvenile idiopathic arthritis
Gerd Horneff,Heinrike Schmeling,T Biedermann,Ivan Foeldvari,Gerd Ganser,HJ Girschick,Toni Hospach,Hans Iko Huppertz,R. Keitzer,R. M. Küster,H Michels,D Moebius,B. Rogalski,A. Thon +13 more
TL;DR: Etanercept treatment was safe and led to a significant improvement in most JIA patients resistant to conventional treatment, and lower in patients with systemic onset arthritis.
Journal ArticleDOI
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.
David A. Isenberg,Elizabeth Allen,Vernon T. Farewell,M. Ehrenstein,Michael G. Hanna,I.E. Lundberg,C. Oddis,Clarissa Pilkington,P. H. Plotz,D. L. Scott,Jiri Vencovsky,Rachel Cooper,Lisa G. Rider,Frederick W. Miller,Elizabeth Adams,Helene Alexanderson,Nancy Armentrout,Zohar Argov,Richard J. Barohn,Suzanne L. Bowyer,Hermine I. Brunner,Rubén Burgos-Vargas,Jeffrey P. Callen,Gail Cawkwell,Patrick Cherin,Yuen-Li Chung,Hanna Chwalińska-Sadowska,Robert D. Cooper,Cronin Me,Katarina Danko,Joyce Davidson,Peter B. Dent,Elizabeth M. Dugan,Brian M. Feldman,Richard Finkel,Ignacio García-De La Torre,Ekkehard Genth,Edward H. Giannini,Gerald J D Hengstman,Jeanne E. Hicks,Adam M. Huber,Hans Iko Huppertz,Lisa Imundo,Kent J. Johnson,Joseph L. Jorizzo,Lawrence Kagen,John T. Kissel,Marisa S. Klein-Gitelman,Abraham Garcia Kutzbach,Bianca Lang,Marissa Lassere,Carol B. Lindsley,Daniel J. Lovell,Sue Maillard,Peter N. Malleson,Alberto Martini,Thomas A. Medsger,Kevin J. Murray,Chester V. Oddis,Lauren M. Pachman,Amy Paller,Maria D. Perez,Paul H. Plotz,Dieter Pongratz,Angelo Ravelli,Ann M. Reed,Robert M. Rennebohm,Nicolino Ruperto,Seward Rutkove,Clyde Ryder,Jean Luc Senécal,Georges Serratrice,Jacques Serratrice,David Sherry,Kumaraswamy Sivakumar,Yeong Song,Richard D. Sontheimer,Ira N. Targoff,Maria L. Turner,Basiel van Engelen,Maria L. Villalba,Kelly Vincent,Victoria P. Werth,Patience H. White,James Witter,Robert Wortmann,Steven R. Ytterberg +86 more
TL;DR: The MITAX, MYOACT and MDI tools, which are now undergoing validity testing, should enhance the consistency, comprehensiveness and reliability of disease activity and damage assessment in patients with myositis.
Journal ArticleDOI
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
Nicolino Ruperto,Daniel J. Lovell,Pierre Quartier,Eliana Paz,Nadina Rubio-Pérez,Clovis A. Silva,Carlos Abud-Mendoza,Ruben Burgos-Vargas,Valeria Gerloni,José Melo-Gomes,Claudia Saad-Magalhães,Jose Chavez-Corrales,Christian Huemer,Alan Kivitz,Francisco J. Blanco,Ivan Foeldvari,Michael Hofer,Gerd Horneff,Hans Iko Huppertz,Chantal Job-Deslandre,Anna Loy,Kirsten Minden,Marilynn Punaro,Alejandro Flores Nunez,Leonard H. Sigal,Alan J. Block,Marleen Nys,Alberto Martini,Edward H. Giannini +28 more
TL;DR: Abatacept provided clinically significant and durable efficacy in patients with JIA, including those who did not initially achieve an ACR Pedi 30 response during the initial 4-month open-label lead-in phase.
Journal ArticleDOI
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis
Nicolino Ruperto,Angelo Ravelli,Kevin J. Murray,Daniel J. Lovell,Boel Andersson-Gäre,Brian M. Feldman,Stella Garay,Wietse Kuis,Claudio Machado,Lauren M. Pachman,AM Prieur,Lisa G. Rider,Earl D. Silverman,Elena Tsitsami,P Woo,Edward H. Giannini,Alberto Martini,Sang Cheol Bae,Zsolt Balogh,Rubén Burgos-Vargas,Carmen De Cunto,Jaime de Inocencio,Pavla Dolezalova,Miroslav Harjacek,Philip J. Hashkes,Michael Hofer,Visa Honkanen,Christian Huemer,Hans Iko Huppertz,Rik Joos,Florence Kanakoudi,Vibke Lilleby,José Melo-Gomes,Dimitrina Mihaylova,Susan Nielsen,Irina Nikishina,Huri Ozdogan,Kharaman Pagava,Anne M. Reed,Robert M. Rennebohm,Anna Maria Romicka,Madeleine Rooney,I. Rumba,Gordana Susic,Richard Vesely +44 more
TL;DR: Preliminary core sets of measures for disease activity and damage assessment in JSLE and JDM are developed and the prospective validation of the core sets is in progress.